Xanthine Oxidoreductase Inhibition with Febuxostat in Adults with Mild Hyperuricaemia and Impaired Glucose Metabolism: a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial in a Prespecified Uric Acid Overproduction Phenotype (XO-FACTOR)

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-526401-15-00

Enrollment

248

Registered

2026-10-19

Start date

Unknown

Completion date

Unknown

Last updated

2026-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiometabolic disease and mild chronic hyperuricemia

Brief summary

HOMA-index change from baseline to study end

Detailed description

Blood pressure profile PWV Chronic eGFR slope from baseline to study end Kidney function: eGFR, Cr, UPCR, UACR, cistatina C Kidney damage: DKK-3 Inflammation: N/L ratio Lipid metabolism: TG, HDL-C, TC, LDL-C, non-HDL-C, TG/HDL-C US UA deposition (subgroup)

Interventions

DRUGFilm-coated tablets

DRUGyellow to pale yellow

DRUGcapsule-shaped

DRUGwith “80” embossed on one side

DRUGFEBUXOSTAT

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
HOMA-index change from baseline to study end	—

Secondary

Measure	Time frame
Blood pressure profile PWV Chronic eGFR slope from baseline to study end Kidney function: eGFR, Cr, UPCR, UACR, cistatina C Kidney damage: DKK-3 Inflammation: N/L ratio Lipid metabolism: TG, HDL-C, TC, LDL-C, non-HDL-C, TG/HDL-C US UA deposition (subgroup)	—

Outcome results

None listed

Source: EU CTIS · Data processed: Oct 20, 2026